Iovance Historical Cash Flow
| IOVA Stock | USD 9.40 0.28 3.07% |
Analysis of Iovance Biotherapeutics cash flow over time is an excellent tool to project Iovance Biotherapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 23.4 M or End Period Cash Flow of 190.4 M as it is a great indicator of Iovance Biotherapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Iovance Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iovance Biotherapeutics is a good buy for the upcoming year.
Iovance |
About Iovance Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Iovance balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Iovance's non-liquid assets can be easily converted into cash.
Iovance Biotherapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Iovance Biotherapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Begin Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 34.8 M, whereas Change In Cash is projected to grow to (54 M).
Iovance Biotherapeutics cash flow statement Correlations
Click cells to compare fundamentals
Iovance Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iovance Biotherapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (62.7M) | 53.4M | 11.5M | 153.8M | (56.8M) | (54.0M) | |
| Free Cash Flow | (165.8M) | (251.9M) | (265.5M) | (313.2M) | (384.1M) | (364.9M) | |
| Change In Working Capital | 10.0M | 3.0M | 24.6M | (2.9M) | (6.5M) | (6.2M) | |
| Begin Period Cash Flow | 82.2M | 19.4M | 72.9M | 84.3M | 238.2M | 250.1M | |
| Depreciation | 1.2M | 1.1M | 14.0M | 21.1M | 33.1M | 34.8M | |
| Capital Expenditures | 6.9M | 46.8M | 37.6M | 20.4M | 22.3M | 23.4M | |
| Total Cash From Operating Activities | (158.9M) | (205.1M) | (227.9M) | (292.8M) | (361.8M) | (343.7M) | |
| Net Income | (197.6M) | (259.6M) | (342.3M) | (395.9M) | (444.0M) | (421.8M) | |
| End Period Cash Flow | 19.4M | 72.9M | 84.3M | 238.2M | 181.3M | 190.4M | |
| Other Cashflows From Financing Activities | 312K | 9.4M | 35.1M | 648K | (322K) | (305.9K) | |
| Total Cash From Financing Activities | 6.1M | 576.4M | 239.3M | 190.2M | 463.0M | 486.1M | |
| Other Non Cash Items | 6.6M | 7.6M | 6.0M | 871K | (3.5M) | (3.4M) | |
| Change To Liabilities | 19.4M | 21.1M | 27.7M | 5.9M | 6.8M | 7.5M | |
| Sale Purchase Of Stock | (312K) | (284K) | 1.6M | (2.6M) | 2.4M | 2.3M | |
| Investments | 96.9M | (271.1M) | 37.7M | 256.5M | (81.9M) | (86.0M) | |
| Total Cashflows From Investing Activities | 90.0M | (317.9M) | 132K | 256.5M | 294.9M | 309.7M | |
| Cash And Cash Equivalents Changes | (63.2M) | (62.7M) | 53.4M | 11.5M | 10.3M | 10.8M | |
| Cash Flows Other Operating | (2.1M) | (2.5M) | (10.6M) | 7.8M | 7.0M | 7.3M | |
| Change To Netincome | 24.0M | 40.9M | 69.8M | 84.9M | 97.6M | 102.5M | |
| Stock Based Compensation | 24.3M | 40.9M | 69.8M | 84.0M | 62.6M | 34.8M | |
| Change To Operating Activities | (2.7M) | 5.9M | 17.6M | (8.8M) | (10.1M) | (9.6M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.29) | Return On Equity (0.57) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.